Interleukin-6 gene –174 C/G and apolipoprotein E gene polymorphisms and the risk of Alzheimer disease in a Polish population
Affiliations- Clinical Department of Neurology, Voivodeship Hospital in Olsztyn
- Chair and Department of Pharmacology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland.
- Department of Neurodegenerative Disorders, Mossakowski Medical Research Centre, Polish Academy of Sciences, Pawińskiego 5, 02-106 Warsaw, Poland
open access
Abstract
Inflammation plays a prominent role in Alzheimer disease (AD) pathogenesis. Interleukin-6 (IL-6), a pro-inflammatory cytokine, and some genetic variations in the IL-6 gene have been reported to be associated with a risk of AD. However, the results of the conducted studies are equivocal.
Material and methodsWe genotyped IL-6 (–174 C/G) and apolipoprotein E gene (APOE) common polymorphisms in a large case-controlled study in a Polish population. We included 361 patients aged ≥ 65 years with AD (mean age 75.8 ± 5.3 years, 232 females [64.3%]) and 200 controls (75.3 ± 7.4 years; 119 females [59.5%]), without any neurological deficit, cognitive complaints or history of neurological diseases. The IL-6 polymorphism was genotyped using TaqMan SNP allelic discrimination by means of an ABI 7900HT (Applied Biosystems, Foster City, CA).
ResultsThe distribution of the IL-6 (–174 C/G) genotypes was similar to that in the controls (AD: C/C = 15.79%, C/G = 51.25%, G/G = 32.96% vs. controls: C/C = 21.50%, C/G = 45.50%, G/G = 33.0%, p > 0.05). Our study confirms previous reports that APOE 4 is strongly related to the risk of AD (OR = 6.17; 95% CI: 4.01–9.49). APOE status did not affect the distribution of the studied IL-6 polymorphism.
ConclusionIL-6 (–174 C/G) polymorphism is not a risk factor for late onset AD in a Polish population.
Abstract
Inflammation plays a prominent role in Alzheimer disease (AD) pathogenesis. Interleukin-6 (IL-6), a pro-inflammatory cytokine, and some genetic variations in the IL-6 gene have been reported to be associated with a risk of AD. However, the results of the conducted studies are equivocal.
Material and methodsWe genotyped IL-6 (–174 C/G) and apolipoprotein E gene (APOE) common polymorphisms in a large case-controlled study in a Polish population. We included 361 patients aged ≥ 65 years with AD (mean age 75.8 ± 5.3 years, 232 females [64.3%]) and 200 controls (75.3 ± 7.4 years; 119 females [59.5%]), without any neurological deficit, cognitive complaints or history of neurological diseases. The IL-6 polymorphism was genotyped using TaqMan SNP allelic discrimination by means of an ABI 7900HT (Applied Biosystems, Foster City, CA).
ResultsThe distribution of the IL-6 (–174 C/G) genotypes was similar to that in the controls (AD: C/C = 15.79%, C/G = 51.25%, G/G = 32.96% vs. controls: C/C = 21.50%, C/G = 45.50%, G/G = 33.0%, p > 0.05). Our study confirms previous reports that APOE 4 is strongly related to the risk of AD (OR = 6.17; 95% CI: 4.01–9.49). APOE status did not affect the distribution of the studied IL-6 polymorphism.
ConclusionIL-6 (–174 C/G) polymorphism is not a risk factor for late onset AD in a Polish population.
Keywords
Alzheimer disease, interleukin-6, APOE, polymorphism, risk factor, Polish population
About this articleTitle
Interleukin-6 gene –174 C/G and apolipoprotein E gene polymorphisms and the risk of Alzheimer disease in a Polish population
Journal
Neurologia i Neurochirurgia Polska
Issue
Pages
537-541
Page views
342
Article views/downloads
570
DOI
10.1016/S0028-3843(14)60149-3
Bibliographic record
Neurol Neurochir Pol 2010;44(6):537-541.
Keywords
Alzheimer disease
interleukin-6
APOE
polymorphism
risk factor
Polish population
Authors
Aleksandra Klimkowicz-Mrowiec
Paweł Wotkow
Karolina Spisak
Aleksandra Maruszak
Maria Styczyńska
Maria Barcikowska
Andrzej Szczudlik
Agnieszka Słowik
